Latest Close
$25.69
News
LBRX
LB Pharmaceuticals Inc News
This news view pulls recent coverage and headlines tied to LBRX.
1y Change
$8.39 (+48.50%)
Market Cap
$736,656,320.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
GlobeNewswire • Mar 27, 2026
Read articleLB Pharmaceuticals Inc.: Q4 Earnings Snapshot
Associated Press Finance • Mar 26, 2026
Read articleLB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire • Mar 26, 2026
Read articleLB Pharmaceuticals Begins Phase 3 Trial of LB-102 in Schizophrenia
MT Newswires • Mar 25, 2026
Read articleLB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
GlobeNewswire • Mar 25, 2026
Read articleLB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
MarketBeat • Mar 20, 2026
Read article